Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10469608 | 0.82 | ACHE (0.32) | — | |
| SCHEMBL27211767 | 0.82 | CHRM1 (0.34) | CA1CA2 | |
| SCHEMBL1706440 | 0.78 | MAPT (0.31) | — | |
| SCHEMBL29243185 | 0.76 | CES2 (0.38) | — | |
| SCHEMBL7760204 | 0.73 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL27966643 | 0.73 | — | — | |
| SCHEMBL29033390 | 0.73 | FAAH (0.30) | — | |
| SCHEMBL839714 | 0.72 | — | — | |
| SCHEMBL620037 | 0.72 | — | — | |
| SCHEMBL7760140 | 0.71 | CA1 (0.31) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2010120662-A2 | BIOAVAILABLE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, HCCS, SCNN1B | CA1 507/4885CA2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.